© 2022 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
February 25, 2022
Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
February 23, 2022
Dr Raymond Douglas discusses real-world adherence to teprotumumab as a treatment for thyroid eye disease.
February 10, 2022
Dr Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DMO resolution.
February 04, 2022
Dr Preeya Gupta walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.
February 01, 2022
Dr Lisa Nijm discusses how utilising a dexamethasone intracanalicular insert after cataract surgery saves time for practices.
January 26, 2022
Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.
January 14, 2022
Dr Ted Leng discusses his presentation, “Variations in Vitreoretinal Physician Utilization of Ancillary Testing: An IRIS Registry Analysis” during Retina Specialty Day at AAO 2021.
January 12, 2022
Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.
December 29, 2021
At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.
December 23, 2021
Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.